Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, “7+3”) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Study Information
Alliance Study ID: MM1YA-A04
NCT Study ID (ClinicalTrials.gov): NCT06917911
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: Celalettin Ustun
Status: RECRUITING
Study Description
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin (“7+3” regimen), for the treatment of patients with core binding factor acute myeloid leukemia (CBF-AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to an antitumor antibiotic drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with cytarabine and daunorubicin may have fewer side effects and be as effective or better than the combination with gemtuzumab ozogamicin in treating patients with core binding factor AML.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (23)
Kootenai Health – Coeur d’Alene
Coeur d’Alene, Idaho 83814
United States
Kootenai Clinic Cancer Services – Post Falls
Post Falls, Idaho 83854
United States
Kootenai Clinic Cancer Services – Sandpoint
Sandpoint, Idaho 83864
United States
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky 40202
United States
UofL Health Medical Center Northeast
Louisville, Kentucky 40245
United States
Trinity Health IHA Medical Group Hematology Oncology – Brighton
Brighton, Michigan 48114
United States
Trinity Health IHA Medical Group Hematology Oncology – Canton
Canton, Michigan 48188
United States
Trinity Health IHA Medical Group Hematology Oncology – Chelsea Hospital
Chelsea, Michigan 48118
United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan 48341
United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
United States
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi 39705
United States
Baptist Cancer Center-Grenada
Grenada, Mississippi 38901
United States
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi 38652
United States
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi 38655
United States
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi 38671
United States
Bozeman Health Deaconess Hospital
Bozeman, Montana 59715
United States
Benefis Sletten Cancer Institute
Great Falls, Montana 59405
United States
Community Medical Center
Missoula, Montana 59804
United States
University of Rochester
Rochester, New York 14642
United States
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee 38017
United States
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee 38120
United States
Gundersen Lutheran Medical Center
La Crosse, Wisconsin 54601
United States
Data Sources & Contacts
Full trial details
For more Information